Delivering innovative solutions by connecting technology and business to drive sustainable growth

08 June 2021

Andreas Fischer (CIO)





As ONE Evonik, innovation is deeply rooted in group strategy

Leading beyond chemistry to drive sustainable growth and profitability

Ongoing portfolio transformation


 Target: Specialty portfolio with 100% growth businesses

Ambitious financial targets

■ EBITDA margin: 18-20%

Cash conversion ratio: >40%

ROCE: 11%



Innovation & Sustainability as growth drivers

- €1 bn additional sales from innovation growth fields by 2025
- Growing portfolio share of "Next Generation Solutions"

Performance-driven corporate culture

- Further drive gender and cultural diversity
- Deliver on efficiency programs in Administration & Operations



The ONE Evonik strategy is reflected in our new RD&I setup

ONE Evonik ONE RD&I ONE Portfolio Executive Board Research, Development & Innovation 令 - Leverage Synergies ("Speed of Light" - mRNA) - Integrate sustainability in PARC analysis Performance Specialty Nutrition & Smart Technology & Additives Care Materials Materials Infrastructure Regions Research, Development & Innovation 今



Our strategy

with an aligned set of goals contributing to Evonik's success

We deliver innovative solutions by connecting technology & business to drive sustainable growth



Sustainability


We develop sustainable solutions

as a key factor in decision-making and key success factor for **future growth**



We create opportunities

to achieve our financial target of €1 bn additional sales by 2025 with products of our six innovation growth fields



We make the best use

of our resources with **shared technology platforms** and focus on our most promising projects

Our activities...

- Deliver R&D on new product and processes
- Create & grow businesses beyond core
- Recruit and develop new talents

- Steer portfolio and optimize resource allocation
- Manage partnerships with key customers, startups and universities
- Build reputation as a seal of quality for customers, investors, employees and talents




Bundling our biotechnology competencies into one platform

Consistent focus on future topics

Biotechnology Platform Program & Project Management Process Biotechnology Systems Biotechnology ~200 employees Microbial In silico Target Factory **Process Design** > 100 products **Systems Systems Systems Success Stories Gut Health Solutions** Veramaris **Biosurfactants Lab Operations**



With Creavis as the dedicated unit for business incubation, Evonik gains an effective lever to foster its growth ambitions



| 08 June 2021 | Andreas Fischer | Research & Development



Venture Capital activities driven by strategic goals and financial returns

Powerful partner fostering growth opportunities with entrepreneurs to expand boundaries

Investment principles

- Direct investments in global innovation leaders with disruptive technologies and business models
- Selective fund investments in key geographies and Evonik areas of interest
- Syndication with top tier (corporate) venture capital funds
- Investments in early-to-growth and later-stage companies (sweet spot lying in Series A & B rounds) with established proof of concept (sweet spot at Technology Readiness Level 5 to 6)
- Total investment of up to €15 million over the lifecycle of the investment
- Maintaining minority shareholding, typically between 10 and 20%
- Active partner that often serves on boards











Leading in Innovation – Growth fields and sales target

On track to achieve target of >€1 bn sales from innovation

Innovation Growth Fields







Advanced Food Ingredients

Additive Manufacturing

Sustainable Nutrition



Cosmetic Solutions



Membranes




Health Care Solutions



Sizeable sales base established in all growth fields

Above-average margin contribution

Sales contribution Innovation Growth Fields






Next Generation Solutions addressing Evonik's "Sustainability Focus Areas"

Directly linked to UN SDGs, Innovation Growth Fields and future programs

Our four "Sustainability Focus Areas"









Drive Circularity



Linerless labels





Safeguard Ecosystems







Ensure Health & Well-Being







Membranes



Membranes for gas separation

hybrid technology to extract

Fully integrated, membrane-based

hydrogen from natural gas pipelines.



Silicones for UV curable labels

Enable customers to reduce 40% of material consumption and conserve resources (400t CO₂)

Biosurfactants



Rhamnolipids for cleaning

Based on deforestation-free raw materials & 100% renewable energy for production.

Drug Delivery Systems



LNPs for mRNA encapsulation

Targeted drug delivery to fight diseases such as COVID 19 with the new mRNA technology.



